IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData GlobalData May 31, 2024 According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients…
